A global phase 2 trial found that giving durvalumab plus chemotherapy before surgery enabled most patients with resectable or borderline resectable non-small-cell lung cancer to have an operation, with encouraging pathological complete response rates and no new safety concerns.
Neoadjuvant durvalumab with chemotherapy lets most lung cancer patients undergo surgery
A global phase 2 trial found that giving durvalumab plus chemotherapy before surgery enabled most patients with resectable or borderline resectable non-small-cell lung cancer to have an operation, with encouraging pathological complete response rates and no new safety concerns.
Non-small-cell lung cancer · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.